CCR8 positive Tregs and Their Correlation with Immunotherapy Response in Advanced Non-Small Cell Lung Cancer (NSCLC)
The chemokine receptor CCR8 is selectively expressed on activated regulatory T cells (Tregs), which are recognized as potent immunosuppressive modulators within the tumor microenvironment. Several clinical trials are currently evaluating the therapeutic benefit of selectively depleting these cells to enhance the efficacy of immune checkpoint inhibitors (ICIs). However, the prognostic and predictive value of activated […]
Tertiary Lymphoid Structures as Predictors of Immune Checkpoint Inhibitor Efficacy in NSCLC & the Development of an Ex Vivo Model for Precision Medicine
Tertiary lymphoid structures (TLS) emerge as essential players in modulating anti-tumor immune responses and shaping the outcomes of immune checkpoint inhibitor (ICI) therapies. Here we explored, on the one hand, the impact of TLS maturity on clinical outcomes in non-small cell lung cancer (NSCLC), and introduce, on the other hand, a novel ex vivo tool […]
Impact of Immune Contexture on Immunotherapy Response in NSCLC: Insights from Multiplex IHC and Machine Learning-Based Phenotyping
Predicting which NSCLC patients will benefit from immunotherapy requires more than measuring a single biomarker. Our previous work has helped show that key spatial features of the tumor microenvironment—such as mature tertiary lymphoid structures (Nature Cancer, 2021; Cell Reports Medicine, 2025) and macrophage infiltration within the tumor compartment (Journal for ImmunoTherapy of Cancer, 2022)—are closely associated with treatment outcome. Building […]
Regorafenib plus avelumab in advanced neuroendocrine tumors — and the IDO1 biomarker that predicts resistance
High grade serous ovarian cancer ascites exhibit an impaired immune environment – immunosuppressive & protumoral – detrimental to the immune response
Background Malignant ovarian cancer ascites are increasingly recognized as major contributors to tumorigenesis and cancer progression. Ascites create a complex microenvironment where tumor cells interact with soluble mediators, metabolic factors, and immune cells. These interactions can influence tumor behavior, immune response, and treatment sensitivity. Characterizing the immune and metabolic composition of ovarian cancer ascites, together […]
Why do some mature-TLS lung cancers resist immunotherapy? Two CAF subsets that drive primary resistance in NSCLC
Why do gastric cancers resist PD-1 plus antiangiogenesis? Spatial and plasma profiling points to M2 macrophages
Can an oncolytic virus turn “cold” sarcomas hot? Intratumoral JX-594 with avelumab raised CD8 T cells but not responses
Does metronomic trabectedin reprogram the sarcoma immune microenvironment? A macrophage-and-T-cell shift that tracks with better outcomes
Why IDO1 in inflamed TLS-positive lung tumors predicts immunotherapy response — and marks who might benefit from IDO1 inhibitors
